Journals / ANKEM Dergisi / 2012 / Cilt: 26 - Sayı: 4

The old and new treatment options for vancomycin-resistant enterococcal infections

Vankomisine dirençli enterokok infeksiyonlarının tedavisinde eski ve yeni tedavi seçenekleri

Pages
215–227
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the current and possible future therapeutic options for the management of infections caused by vancomycin resistant enterococci were discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Vancomycin-resistant enterococci are important causes of nosocomial infections occurring in especially critical care or immunocompromised patients.
📊
Key Findings & Data:These organisms cause increased mortality and costs, as well as limited treatment options.
💡
Conclusion & Impact:In this review, the current and possible future therapeutic options for the management of infections caused by vancomycin resistant enterococci were discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Vancomycin-resistant enterococci are important causes of nosocomial infections occurring in especially critical care or immunocompromised patients. These organisms cause increased mortality and costs, as well as limited treatment options. The optimal therapy for these infections is not well established and clinical data are usually limited to case reports, animal models and sporadic experiences. In this review, the current and possible future therapeutic options for the management of infections caused by vancomycin resistant enterococci were discussed.

Özet

Vankomisine dirençli enterokoklar (VRE) özellikle yoğun bakım ve immünsüprese hastalarda önemli bir hastane kaynaklı infeksiyon nedenidirler. Hem mortalitesi ve maliyeti yüksek hem de tedavisi zor infeksiyonlara neden olurlar. VRE infeksiyonlarında kullanılabilecek en iyi tedavi yöntemi tam olarak belirlenememiştir. Klinik veriler daha çok olgu raporları, hayvan deneyleri ve uzman görüşlerine dayanmaktadır. Bu yazıda VRE infeksiyonlarında kullanılabilecek eski ve yeni tedavi seçenekleri gözden geçirilmiştir.

🔖

Cite This Article

TÜNGER, Ö. (2012). The old and new treatment options for vancomycin-resistant enterococcal infections. ANKEM Dergisi, Cilt: 26 - Sayı: 4, 215–227. https://ajindex.com/articles/355021

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections, Clin Microbiol Infect 2010;16(6):555-62. http://dx.doi.org/10.1111/j.1469-0691.2010. 03214.x/10.1097/INF.0b013e3181e78efc PMid: 20569266 2.Arias CA, Mendes RE, Stilwell MG, Jones RN, Murray BE. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections, Clin Infect Dis 2012; 54(Suppl 3):S233-8. http://dx.doi.org/10.1093/cid/cir924 PMid: 22431854 3.Arias CA, Panesso D, McGrath DM et al. Genetic basis for in vivo daptomycin resistance in enterococci, N Engl J Med 2011;365(10):892-900. http://dx.doi.org/10.1056/NEJMoa1011138 PMid: 21899450 4.Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data, Clin Infect Dis 2005;41(Suppl 5):S354-67. http://dx.doi.org/10.1086/431676 PMid: 16080073 5.Bagga B, Shenep JL. Management of infections caused by vancomycin-resistant gram-positive bacteria, Pediatr Infect Dis J 2010;29(7):662-4. http://dx.doi.org PMid: 20574403 6.Barrett JF. Recent developments in glycopeptide antibacterials, Curr Opin Investig Drugs 2005;6(8): 781-90. PMid: 16121684 7.Bethea JA, Walko CM, Targos PA. Treatment of vancomycin-resistant Enterococcus with quinupristin/dalfopristin and high-dose ampicillin, Ann Pharmacother 2004;38(6):989-91. http://dx.doi.org/10.1345/aph.1D377 PMid: 15100393 8.Birmingham MC, Rayner CR, Meagher AK et al. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program, Clin Infect Dis 2003;36(2):159-68. http://dx.doi.org/10.1086/345744 PMid: 12522747 9.Brandt CM, Rouse MS, Laue NW, Stratton CW, Wilson WR, Steckelberg JM. Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents, J Infect Dis 1996;173(4):909-13. http://dx.doi.org/10.1093/infdis/173.4.909 PMid: 8603970 10.Centers for Disease Control and Prevention. National Nosocomial Infection Surveillance (NNIS) System: report, data summary from January 1992 through June 2003, issued August 2003, Am J Infect Control 2003;31(8):481-98. http://dx.doi.org/10.1016/j.ajic.2003.09.002 PMid: 14647111 11.Cervera C, Castañeda X, Pericas JM et al. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci, Int J Antimicrob Agents 2011;38(5):365-70. h